| SOSUI: classification and secondary structure prediction system for membrane proteins. T Hirokawa, S Boon-Chieng, S Mitaku Bioinformatics (Oxford, England) 14 (4), 378-379, 1998 | 2323 | 1998 |
| Ubiquitin is phosphorylated by PINK1 to activate parkin F Koyano, K Okatsu, H Kosako, Y Tamura, E Go, M Kimura, Y Kimura, ... Nature 510 (7503), 162-166, 2014 | 1490 | 2014 |
| Structural basis for a broad but selective ligand spectrum of a mouse olfactory receptor: mapping the odorant-binding site S Katada, T Hirokawa, Y Oka, M Suwa, K Touhara Journal of Neuroscience 25 (7), 1806-1815, 2005 | 364 | 2005 |
| Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands K Kawajiri, Y Kobayashi, F Ohtake, T Ikuta, Y Matsushima, J Mimura, ... Proceedings of the national academy of sciences 106 (32), 13481-13486, 2009 | 292 | 2009 |
| Amphiphilicity index of polar amino acids as an aid in the characterization of amino acid preference at membrane–water interfaces S Mitaku, T Hirokawa, T Tsuji Bioinformatics 18 (4), 608-616, 2002 | 282 | 2002 |
| Multiple functions of precursor BDNF to CNS neurons: negative regulation of neurite growth, spine formation and cell survival H Koshimizu, K Kiyosue, T Hara, S Hazama, S Suzuki, K Uegaki, ... Molecular brain 2, 1-19, 2009 | 216 | 2009 |
| Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants K Nishikawa, H Li, R Kawamura, H Osaka, YL Wang, Y Hara, T Hirokawa, ... Biochemical and biophysical research communications 304 (1), 176-183, 2003 | 211 | 2003 |
| Analysis of multiple compound–protein interactions reveals novel bioactive molecules H Yabuuchi, S Niijima, H Takematsu, T Ida, T Hirokawa, T Hara, T Ogawa, ... Molecular systems biology 7 (1), 472, 2011 | 178 | 2011 |
| Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ... Iscience 24 (4), 2021 | 125 | 2021 |
| Physicochemical factors for discriminating between soluble and membrane proteins: hydrophobicity of helical segments and protein length S Mitaku, T Hirokawa Protein engineering 12 (11), 953-957, 1999 | 113 | 1999 |
| Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface Y Toyoda, K Morimoto, R Suno, S Horita, K Yamashita, K Hirata, ... Nature chemical biology 15 (1), 18-26, 2019 | 104 | 2019 |
| Temperature-sensitive substrate and product binding underlie temperature-compensated phosphorylation in the clock Y Shinohara, YM Koyama, M Ukai-Tadenuma, T Hirokawa, M Kikuchi, ... Molecular cell 67 (5), 783-798. e20, 2017 | 88 | 2017 |
| Engineering PQQ glucose dehydrogenase with improved substrate specificity: site-directed mutagenesis studies on the active center of PQQ glucose dehydrogenase S Igarashi, T Hirokawa, K Sode Biomolecular engineering 21 (2), 81-89, 2004 | 77 | 2004 |
| Crystal structures of human orexin 2 receptor bound to the subtype-selective antagonist EMPA R Suno, KT Kimura, T Nakane, K Yamashita, J Wang, T Fujiwara, ... Structure 26 (1), 7-19. e5, 2018 | 76 | 2018 |
| Proportion of membrane proteins in proteomes of 15 single-cell organisms analyzed by the SOSUI prediction system S Mitaku, M Ono, T Hirokawa, S Boon-Chieng, M Sonoyama Biophysical Chemistry 82 (2-3), 165-171, 1999 | 76 | 1999 |
| Molecular mechanisms for sweet-suppressing effect of gymnemic acids K Sanematsu, Y Kusakabe, N Shigemura, T Hirokawa, S Nakamura, ... Journal of Biological Chemistry 289 (37), 25711-25720, 2014 | 72 | 2014 |
| GRIFFIN: a system for predicting GPCR–G-protein coupling selectivity using a support vector machine and a hidden Markov model Y Yabuki, T Muramatsu, T Hirokawa, H Mukai, M Suwa Nucleic acids research 33 (suppl_2), W148-W153, 2005 | 72 | 2005 |
| Generation of KS-58 as the first K-Ras (G12D)-inhibitory peptide presenting anti-cancer activity in vivo K Sakamoto, T Masutani, T Hirokawa Scientific reports 10 (1), 21671, 2020 | 70 | 2020 |
| Multidrug treatment with nelfinavir and cepharanthine against COVID-19 H Ohashi, K Watashi, W Saso, K Shionoya, S Iwanami, T Hirokawa, ... BioRxiv, 2020.04. 14.039925, 2020 | 69 | 2020 |
| Current challenges and opportunities in designing protein–protein interaction targeted drugs WH Shin, K Kumazawa, K Imai, T Hirokawa, D Kihara Advances and Applications in Bioinformatics and Chemistry, 11-25, 2020 | 67 | 2020 |
